Evidence map›Paper›PMID 36202784›Full record

ArticlemAbs

Fast-tracking antibody maturation using a B cell-based display system.

Hitomi Masuda, Atsushi Sawada, Shu-Ichi Hashimoto, Kanako Tamai, Ke-Yi Lin, Naoto Harigai, Kohei Kurosawa, Kunihiro Ohta, Hidetaka Seo, Hiroshi Itou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hitomi MasudaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Atsushi SawadaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.ORCID 0000-0002-6081-8643
Shu-Ichi HashimotoResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kanako TamaiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Ke-Yi LinResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.ORCID 0000-0001-7868-7904
Naoto HarigaiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kohei KurosawaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kunihiro OhtaDepartment of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
Hidetaka SeoDepartment of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-8676-8955
Hiroshi ItouResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Tokyo University of the Arts · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Affinity maturation, an essential component of antibody engineering, is crucial for developing therapeutic antibodies. Cell display system coupled with somatic hypermutation (SHM) initiated by activation-induced cytidine deaminase (AID) is a commonly used technique for affinity maturation. AID introduces targeted DNA lesions into hotspots of immunoglobulin (Ig) gene loci followed by erroneous DNA repair, leading to biased mutations in the complementary determining regions. However, systems that use an

Indexed as

Cytidine DeaminaseSomatic Hypermutation, ImmunoglobulinAnimalsB-LymphocytesDNAHumansImmunoglobulin GMiceCytidine DeaminaseDNAImmunoglobulin Gactivation-induced cytidine deaminaseAffinity maturationcoldspotdeep sequencingDT40hotspotsomatic hypermutationtherapeutic antibodies

Identifiers

PMID36202784
PMCPMC9542628
OpenAlexW4302774306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.